

Please cancel Claims 1-5, 14, and 29, without prejudice.

Please amend Claims 15-19 as follows:

15. (Amended) A monoclonal antibody to human IL-12 which consists of a p35 subunit and a p40 subunit forming a p75 heterodimer, wherein said monoclonal antibody (a) immunologically reacts with an epitope presented by the p75 heterodimer of human IL-12, but is not immunologically reactive with any epitope presented by said p40 subunit; and

(b) neutralizes at least about 90% of the bioactivity of human IL-12, wherein the antibody neutralizes at least about 90% bioactivity of human IL-12 by inhibiting IL-12 stimulated PHA-activated human lymphoblast proliferation wherein the concentration of said antibody is 0.5 μ g/ml and the concentration of said human IL-12 is 0.25 ng/ml.

D1

16. (Amended) A monoclonal antibody to human IL-12 which consists of a p35 subunit and a p40 subunit forming a p75 heterodimer, wherein said monoclonal antibody

(a) immunologically reacts with an epitope presented by the p75 heterodimer of human IL-12, but is not immunologically reactive with any epitope presented by said p40 subunit; and

(b) neutralizes at least about 90% of the bioactivity of human IL-12, wherein the antibody neutralizes at least about 90% bioactivity of human IL-12 by inhibiting IL-12 stimulated IFN- γ production wherein the concentration of the antibody is 0.5 μ g/ml and the concentration of said human IL-12 is 0.25 ng/ml.

17. (Amended) The antibody of claim 15, wherein the antibody cross reacts with rhesus monkey IL-12.